Home＞BUSINESS
Sanofi, Asahi Kasei Pharma Tie Up for Anti RA Treatment Kevzara(Dec.11.2017)
Sanofi and Asahi Kasei Pharma said on December 8 that they have entered into a license agreement for the marketing of Sanofi’s rheumatoid arthritis (RA) treatment Kevzara subcutaneous injection (sarilumab) in Japan ...
(LOG IN FOR FULL STORY)
-
- Toho Grabs 8% Stake in NKT Cell Immunotherapy Startup Apr.19
- Astellas Sells Agensys Research Facilities to Kite Apr.19
- US Appeals Court Favors Sumitomo Dainippon in Latuda Substance Patent Suit Apr.19
- FDA Clears Kyowa Kirin/Ultragenyx’s XLH Drug Burosumab Apr.19
- Tecentriq Now in PD-1/L1 NSCLC Showdown, Lynparza Also Hits Japan Market Apr.19
- Biosimilar Use Essential to Sustain Universal Health Coverage: Society President(Apr.19)
- MHLW Sees Solid Inquiry Numbers for Conditional Early Approval System: Official(Apr.19)
- Toho Grabs 8% Stake in NKT Cell Immunotherapy Startup(Apr.19)
- Astellas Sells Agensys Research Facilities to Kite(Apr.19)
- US Appeals Court Favors Sumitomo Dainippon in Latuda Substance Patent Suit(Apr.19)
